Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Advances in advanced renal cell carcinoma from ESMO 2012: Part 1

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.10.12
Views: 14842

Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA


Professor Tim Eisen from Addenbrooke's Oncology Centre, Cambridge, talks to ecancer TV with Dr Bernard Escudier from Institut Gustave Roussy, France, Dr Thomas Powles from St Bartholomew Hospital, London, and Dr Thomas Hutson from Baylor Sammons Cancer Center, USA. The experts outline results from the major studies reporting at ESMO 2012 in mRCC. 


The COMPARZ study reports on PFS, adverse events and quality of life with pazopanib vs. sunitinib.  The panel discusses how these data compare with those from PISCES, and the implications of these results on clinical practice.  They comment on on-going studies that may lead to an impact on first-line standard of care in mRCC, for example, studies with axitinib and tivozanib. 


This programme has been supported by an educational grant from GlaxoSmithKline.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation